Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CL
Cellectar Biosciences INC NEW
CLRB
Mkt Cap
$10.7M
Volume
335.82K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CL
CLRB
CL
Cellectar Biosciences INC NEW
CLRB
News
·
Waldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements | DelveInsight
Mkt Cap
$10.8M
Volume
335.82K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Insider
Filings
Waldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements | DelveInsight
The Waldenstrom macroglobulinemia market is experiencing steady growth driven by advances in targeted therapies, particularly BTK inhibitors. Rising awareness, improved diagnostics, and increasing clinical trials are propelling market expansion, with several emerging drugs showing promise in treating this rare lymphoma.
GlobeNewswire Inc. · Jul 14, 2025
Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q
Cellectar Biosciences, Inc. announced that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing restated financial statements for 2022, 2023, and the first half of 2024.
GlobeNewswire Inc. · Nov 1, 2024
Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq
Cellectar Biosciences, Inc. announced that it needs to restate its previously issued financial statements due to a review of its accounting treatment for warrants issued in a 2022 financing. The company has received a delinquency notification from Nasdaq and has 60 days to submit a plan to regain compliance.
GlobeNewswire Inc. · Aug 23, 2024
Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape
Event scheduled for Wednesday, July 24, 2024, at 8:00 am EDT Event scheduled for Wednesday, July 24, 2024, at 8:00 am EDT
GlobeNewswire Inc. · Jun 27, 2024
Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides
Opportunity for Iopofosine Expansion Within Areas of High Unmet Need in Non-Hodgkin’s Lymphoma
GlobeNewswire Inc. · May 29, 2024
Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update
Management to host a conference call today at 8:30 am ET
GlobeNewswire Inc. · May 14, 2024
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer of Cellectar, will present an overview of the company in a fireside chat at the upcoming Guggenheim Healthcare Talks Radiopharmaceuticals Day being held on May 13, 2024 in New York City. Details of the fireside chat are as follows:
GlobeNewswire Inc. · May 8, 2024
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024
FLORHAM PARK, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will report its financial results for the three months ended March 31, 2024, on Tuesday, May 14, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern Time. Details for the call are as follows:
GlobeNewswire Inc. · May 7, 2024
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
Management to host a conference call today at 8:30 am ET Management to host a conference call today at 8:30 am ET
GlobeNewswire Inc. · Mar 27, 2024
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will report its financial results for the year ended December 31, 2023, on Wednesday, March 27, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern Time. Details for the call are as follows:
GlobeNewswire Inc. · Mar 20, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
CL
CLRB
Cellectar Biosciences INC NEW
Buy
Sell
Market
Limit
Soon
CLRB
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any CLRB yet.
Related Tickers
Earnings